U.S. Markets open in 9 hrs 3 mins

Proteostatis stock plunges on cystic fibrosis triple combo data

Allison DeAngelis
Proteostatis stock plunges on cystic fibrosis triple combo data

What would otherwise be promising data led to a 60 percent stock price slide, as it falls far below both triple combination treatments being developed by the cystic fibrosis market leader, Vertex.